<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580616</url>
  </required_header>
  <id_info>
    <org_study_id>D18095</org_study_id>
    <nct_id>NCT03580616</nct_id>
  </id_info>
  <brief_title>Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)</brief_title>
  <acronym>ALS</acronym>
  <official_title>Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elijah W. Stommel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brain Chemistry Labs, Institute for Ethnomedicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the tolerability of L-Serine oral doses for ALS
      patients and assess preliminary indications of efficacy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive the same dose of the study treatment over 6 months. For each
      participant the study will last approximately one year with follow up visits after the
      treatment period of 6 months is completed. The visits will include blood draws,
      electromyography (EMG), vital sign checks, neurological and physical exams, pulmonary testing
      with forced vital capacity (FVC), and questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose tolerability based on subject reporting</measure>
    <time_frame>6 months</time_frame>
    <description>Dose tolerability is based on subject interviews and diary assessment evaluating the presence or absence of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy based on ALS Functional Rating Scale - Revised (ALSFRS-R)</measure>
    <time_frame>Baseline, 1 year</time_frame>
    <description>Change in ALSFRS-R questionnaire scale. The ALSFRS-R provides a physician-generated estimate of the patient's degree of functional impairment, which can be evaluated serially to objectively assess any response to treatment or progression of disease. The ALSFRS includes ten questions that ask the physician to rate his/her impression of the patients level of functional impairment in performing one of ten common tasks, e.g. climbing stairs. Each task is rated on a five-point scale from 0 = can't do, to 4 = normal ability. Individual item scores are summed to produce a reported score of between 0=worst and 40=best.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy based on neurological exam</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change in neurological exams with testing of muscle flexion and extension (scale: 0 to 5 with 0 being the most impaired) reflexes (scale: absent to brisk with absent being the most impaired), and sensation (scale: normal to abnormal), cranial nerves (scale: normal to abnormal on ocular movement, yes to no on Ptosis, normal to atrophy on tongue, and normal to abnormal on tongue movement).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy based on pulmonary forced vital capacity</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Change in % predicted in forced vital capacity</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Possible Amyotrophic Sclerosis</condition>
  <arm_group>
    <arm_group_label>L-Serine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>L-Serine 15 grams orally twice a day as tolerated for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Serine</intervention_name>
    <description>L-Serine is a naturally occurring dietary amino acid. It is abundant in soy products, some edible seaweeds, sweet potatoes, eggs and meat.</description>
    <arm_group_label>L-Serine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of probable or definite ALS

          -  ALSFRS-R score &gt;25 and FVC score ≥ 60% predicted

          -  If currently taking Riluzole and Edaravone/Radicava for 3 months prior to
             Baseline/Screening or not at all

        Exclusion Criteria:

          -  Diagnosis of probable or definite ALS more than 3 years prior to study enrollment

          -  Diagnosis or previous history of ischemic stroke, brain tumor, uncontrolled diabetes,
             renal insufficiency, or severe hypertension.

          -  Diagnosis or previous history of comorbid progressive neurodegenerative disease such
             as Alzheimer's disease, Parkinson's disease, Lewy Body disease, Pick's disease,
             Huntington's disease, Progressive Supranuclear palsy. ALS patients diagnosed with
             frontotemporal dementia will not be excluded from this study.

          -  Diagnosis or previous history of symptomatic peripheral neuropathy. Patients with
             findings of peripheral neuropathy on electrodiagnostic tests only but no clinical
             symptoms at the time of enrollment are eligible.

          -  Undergoing any chemotherapy or radiation therapy for any cancer

          -  Any medical condition likely to interfere with the conduct of the trial or survival of
             the patient during this study period

          -  Pregnant women or women who are breast feeding

          -  Has taken L-Serine supplement within 30 days prior to start of study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elijah W Stommel, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Htichcock Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Catherine L. Andrews, RN/CCRN</last_name>
    <phone>603-650-4633</phone>
    <email>Catherine.L.Andrews@hitchcock.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine L. Andrews, RN</last_name>
      <phone>603-650-4633</phone>
      <email>catherine.l.andrews@hitchcock.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H; Edaravone ALS Study Group. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014 Dec;15(7-8):610-7. doi: 10.3109/21678421.2014.959024. Epub 2014 Oct 6.</citation>
    <PMID>25286015</PMID>
  </reference>
  <reference>
    <citation>Andrew AS, Caller TA, Tandan R, Duell EJ, Henegan PL, Field NC, Bradley WG, Stommel EW. Environmental and Occupational Exposures and Amyotrophic Lateral Sclerosis in New England. Neurodegener Dis. 2017;17(2-3):110-116. doi: 10.1159/000453359. Epub 2017 Jan 26.</citation>
    <PMID>28122372</PMID>
  </reference>
  <reference>
    <citation>Brannath W, Burger HU, Glimm E, Stallard N, Vandemeulebroecke M, Wassmer G. Comments on the draft guidance on &quot;adaptive design clinical trials for drugs and biologics&quot; of the U.S. Food and Drug Administration. J Biopharm Stat. 2010 Nov;20(6):1125-31. doi: 10.1080/10543406.2010.514453.</citation>
    <PMID>21058108</PMID>
  </reference>
  <reference>
    <citation>Banack SA, Murch SJ, Cox PA. Neurotoxic flying foxes as dietary items for the Chamorro people, Marianas Islands. J Ethnopharmacol. 2006 Jun 15;106(1):97-104. Epub 2006 Feb 7.</citation>
    <PMID>16457975</PMID>
  </reference>
  <reference>
    <citation>Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995 May-Jun;16(3):271-8; discussion 278-84. Review.</citation>
    <PMID>7566337</PMID>
  </reference>
  <reference>
    <citation>Caller TA, Andrews A, Field NC, Henegan PL, Stommel EW. The Epidemiology of Amyotrophic Lateral Sclerosis in New Hampshire, USA, 2004-2007. Neurodegener Dis. 2015;15(4):202-6. doi: 10.1159/000374117. Epub 2015 Apr 16.</citation>
    <PMID>25896575</PMID>
  </reference>
  <reference>
    <citation>Canu N, Ciotti MT, Pollegioni L. Serine racemase: a key player in apoptosis and necrosis. Front Synaptic Neurosci. 2014 Apr 21;6:9. doi: 10.3389/fnsyn.2014.00009. eCollection 2014. Review.</citation>
    <PMID>24795622</PMID>
  </reference>
  <reference>
    <citation>Cox PA, Banack SA, Murch SJ. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam. Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13380-3.</citation>
    <PMID>14612559</PMID>
  </reference>
  <reference>
    <citation>Cox PA, Davis DA, Mash DC, Metcalf JS, Banack SA. Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. Proc Biol Sci. 2016 Jan 27;283(1823). pii: 20152397. doi: 10.1098/rspb.2015.2397.</citation>
    <PMID>26791617</PMID>
  </reference>
  <reference>
    <citation>de Koning TJ. Treatment with amino acids in serine deficiency disorders. J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):347-51. Review.</citation>
    <PMID>16763900</PMID>
  </reference>
  <reference>
    <citation>Desai JR, Bowen EA, Danielson MM, Allam RR, Cantor MN. Creation and implementation of a historical controls database from randomized clinical trials. J Am Med Inform Assoc. 2013 Jun;20(e1):e162-8. doi: 10.1136/amiajnl-2012-001257. Epub 2013 Feb 28.</citation>
    <PMID>23449762</PMID>
  </reference>
  <reference>
    <citation>Dunlop RA, Cox PA, Banack SA, Rodgers KJ. The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation. PLoS One. 2013 Sep 25;8(9):e75376. doi: 10.1371/journal.pone.0075376. eCollection 2013.</citation>
    <PMID>24086518</PMID>
  </reference>
  <reference>
    <citation>Dunlop RA, Powell J, Guillemin GJ, Cox PA. Mechanisms of L-Serine Neuroprotection in vitro Include ER Proteostasis Regulation. Neurotox Res. 2018 Jan;33(1):123-132. doi: 10.1007/s12640-017-9829-3. Epub 2017 Nov 2.</citation>
    <PMID>29098664</PMID>
  </reference>
  <reference>
    <citation>Dunlop RA, Powell JT, Metcalf JS, Guillemin GJ, Cox PA. L-Serine-Mediated Neuroprotection Includes the Upregulation of the ER Stress Chaperone Protein Disulfide Isomerase (PDI). Neurotox Res. 2018 Jan;33(1):113-122. doi: 10.1007/s12640-017-9817-7. Epub 2017 Oct 3.</citation>
    <PMID>28975502</PMID>
  </reference>
  <reference>
    <citation>Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, Abner EL, Petersen RC, Federoff HJ, Miller BL, Goetzl EJ. Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study. Alzheimers Dement. 2015 Jun;11(6):600-7.e1. doi: 10.1016/j.jalz.2014.06.008. Epub 2014 Aug 15.</citation>
    <PMID>25130657</PMID>
  </reference>
  <reference>
    <citation>Garofalo K, Penno A, Schmidt BP, Lee HJ, Frosch MP, von Eckardstein A, Brown RH, Hornemann T, Eichler FS. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J Clin Invest. 2011 Dec;121(12):4735-45. doi: 10.1172/JCI57549.</citation>
    <PMID>22045570</PMID>
  </reference>
  <reference>
    <citation>Goetzl EJ, Boxer A, Schwartz JB, Abner EL, Petersen RC, Miller BL, Kapogiannis D. Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease. Neurology. 2015 Jul 7;85(1):40-7. doi: 10.1212/WNL.0000000000001702. Epub 2015 Jun 10.</citation>
    <PMID>26062630</PMID>
  </reference>
  <reference>
    <citation>Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the &quot;common&quot; neurologic disorders? Neurology. 2007 Jan 30;68(5):326-37.</citation>
    <PMID>17261678</PMID>
  </reference>
  <reference>
    <citation>Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF, Camu W, Meininger V, Dupre N, Rouleau GA. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008 May;40(5):572-4. doi: 10.1038/ng.132. Epub 2008 Mar 30.</citation>
    <PMID>18372902</PMID>
  </reference>
  <reference>
    <citation>Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, Rowland LP, Levin B, Mitsumoto H. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005 Jan 11;64(1):38-43.</citation>
    <PMID>15642901</PMID>
  </reference>
  <reference>
    <citation>Logroscino G, Traynor BJ, Hardiman O, Chiò A, Mitchell D, Swingler RJ, Millul A, Benn E, Beghi E; EURALS. Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010 Apr;81(4):385-90. doi: 10.1136/jnnp.2009.183525. Epub 2009 Aug 25.</citation>
    <PMID>19710046</PMID>
  </reference>
  <reference>
    <citation>Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, Muravov O, Horton K. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013. MMWR Surveill Summ. 2016 Aug 5;65(8):1-12. doi: 10.15585/mmwr.ss6508a1.</citation>
    <PMID>27490513</PMID>
  </reference>
  <reference>
    <citation>Metcalf JS, Dunlop RA, Powell JT, Banack SA, Cox PA. L-Serine: a Naturally-Occurring Amino Acid with Therapeutic Potential. Neurotox Res. 2018 Jan;33(1):213-221. doi: 10.1007/s12640-017-9814-x. Epub 2017 Sep 19. Review.</citation>
    <PMID>28929385</PMID>
  </reference>
  <reference>
    <citation>Metcalf JS, Lobner D, Banack SA, Cox GA, Nunn PB, Wyatt PB, Cox PA. Analysis of BMAA enantiomers in cycads, cyanobacteria, and mammals: in vivo formation and toxicity of D-BMAA. Amino Acids. 2017 Aug;49(8):1427-1439. doi: 10.1007/s00726-017-2445-y. Epub 2017 Jun 15.</citation>
    <PMID>28620737</PMID>
  </reference>
  <reference>
    <citation>Murch SJ, Cox PA, Banack SA. A mechanism for slow release of biomagnified cyanobacterial neurotoxins and neurodegenerative disease in Guam. Proc Natl Acad Sci U S A. 2004 Aug 17;101(33):12228-31. Epub 2004 Aug 4.</citation>
    <PMID>15295100</PMID>
  </reference>
  <reference>
    <citation>Phukan J, Elamin M, Bede P, Jordan N, Gallagher L, Byrne S, Lynch C, Pender N, Hardiman O. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):102-8. doi: 10.1136/jnnp-2011-300188. Epub 2011 Aug 11.</citation>
    <PMID>21836033</PMID>
  </reference>
  <reference>
    <citation>Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 2008 Mar 25;70(13 Pt 2):1134-40. doi: 10.1212/01.wnl.0000306410.84794.4d.</citation>
    <PMID>18362273</PMID>
  </reference>
  <reference>
    <citation>Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005 Aug 23;65(4):586-90.</citation>
    <PMID>16116120</PMID>
  </reference>
  <reference>
    <citation>Spławiński J, Kuźniar J. Clinical trials: active control vs placebo--what is ethical? Sci Eng Ethics. 2004 Jan;10(1):73-9. Review.</citation>
    <PMID>14986774</PMID>
  </reference>
  <reference>
    <citation>Thall PF, Simon RM, Estey EH. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat Med. 1995 Feb 28;14(4):357-79.</citation>
    <PMID>7746977</PMID>
  </reference>
  <reference>
    <citation>Thompson AG, Gray E, Heman-Ackah SM, Mäger I, Talbot K, Andaloussi SE, Wood MJ, Turner MR. Extracellular vesicles in neurodegenerative disease - pathogenesis to biomarkers. Nat Rev Neurol. 2016 Jun;12(6):346-57. doi: 10.1038/nrneurol.2016.68. Epub 2016 May 13. Review.</citation>
    <PMID>27174238</PMID>
  </reference>
  <reference>
    <citation>Viele K, Berry S, Neuenschwander B, Amzal B, Chen F, Enas N, Hobbs B, Ibrahim JG, Kinnersley N, Lindborg S, Micallef S, Roychoudhury S, Thompson L. Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014 Jan-Feb;13(1):41-54. doi: 10.1002/pst.1589. Epub 2013 Aug 5. Review.</citation>
    <PMID>23913901</PMID>
  </reference>
  <reference>
    <citation>Wheaton MW, Salamone AR, Mosnik DM, McDonald RO, Appel SH, Schmolck HI, Ringholz GM, Schulz PE. Cognitive impairment in familial ALS. Neurology. 2007 Oct 2;69(14):1411-7.</citation>
    <PMID>17909153</PMID>
  </reference>
  <reference>
    <citation>Winston CN, Goetzl EJ, Akers JC, Carter BS, Rockenstein EM, Galasko D, Masliah E, Rissman RA. Prediction of conversion from mild cognitive impairment to dementia with neuronally derived blood exosome protein profile. Alzheimers Dement (Amst). 2016 May 7;3:63-72. doi: 10.1016/j.dadm.2016.04.001. eCollection 2016.</citation>
    <PMID>27408937</PMID>
  </reference>
  <reference>
    <citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Dec;1(5):293-9. Review.</citation>
    <PMID>11464847</PMID>
  </reference>
  <reference>
    <citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999 Oct 31;169(1-2):13-21.</citation>
    <PMID>10540002</PMID>
  </reference>
  <reference>
    <citation>Levine TD, Miller RG, Bradley WG, Moore DH, Saperstein DS, Flynn LE, Katz JS, Forshew DA, Metcalf JS, Banack SA, Cox PA. Phase I clinical trial of safety of L-serine for ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):107-111. doi: 10.1080/21678421.2016.1221971. Epub 2016 Sep 2.</citation>
    <PMID>27589995</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>Elijah W. Stommel</investigator_full_name>
    <investigator_title>staff physician, Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

